// App-Quantinova.ai

OR4‐021 : The real world use of bosutinib in patients with chronic myeloid leukaemia

Researchers

Presenter

  • J Apperley

Principal Investigators

  • J Byrne

  • G Smith

  • S Claudiani

  • J Janssen

  • A Viqueira

  • K Lang

  • A Carter

  • G Nock

  • D Milojkovic

Medical Centers

  • Imperial College Healthcare NHS Trust, London,

  • Nottingham University Hospitals NHS Trust, Nottingham,

  • Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom

  • VU University Medical Center, Amsterdam, Netherlands

  • Pfizer Spain, Madrid, Spain

  • Pfizer Ltd, Walton‐on‐the‐Hill

  • pH Associates Ltd, Marlow, United Kingdom

Locations

  • United Kingdom

  • Netherlands

  • Spain

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Breakpoint Cluster Region

  • Ph chromosome

  • Cluster of Differentiation 206

Drug/Treatment

  • Bosutinib

  • Nilotinib

  • dasatinib

  • Imatinib

  • IkT001

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • Multinational

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved